AM Best Revises Outlooks to Negative For Dhipaya Insurance Public Company Limited
SINGAPORE--(BUSINESS WIRE)--AM Best has revised the outlooks to negative from stable and affirmed the Financial…
6 years ago
Wire Stories
India Live Event Market Report 2020: Ticketed Events, Event Category, Future Outlook, Event Offerings in Percent – ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "India Live Event Market, Ticketed Events, Event Category, Future Outlook, Event Offerings in…
6 years ago
Kulicke & Soffa Declares Regular Quarterly Dividend of $0.12
SINGAPORE--(BUSINESS WIRE)--Kulicke and Soffa Industries, Inc. (NASDAQ: KLIC) (“Kulicke & Soffa,” “K&S” or the “Company”),…
6 years ago
Kulicke & Soffa Appoints Jeff Richardson to its Board of Directors
SINGAPORE--(BUSINESS WIRE)--Kulicke and Soffa Industries, Inc. (NASDAQ: KLIC) ("Kulicke & Soffa," "K&S" or the "Company")…
6 years ago
KartRider Rush+ Surpasses 10 Million Global Downloads Within Two Weeks!
Nexon’s Thrilling Mobile Racer Adds Three New Tracks and New Character ‘Dino Ethen’ LOS ANGELES--(BUSINESS…
6 years ago
TriLinc Global Impact Fund Makes Impact Investment in Latin America
TriLinc Global Impact Fund announced today that it recently approved a $3,250,000 term loan transaction,…
6 years ago
COVID-19 Case Study: Retailers Reactions in China 2020 – Lin Qingxuan, Nike, Meituan Dianping, JD.com, Alibaba, and Hema – ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Retailer Reactions in China: Coronavirus (COVID-19) - Case Study" report has been added…
6 years ago
Impact of COVID-19 on the Retail Sector in China, 2020 – Consumer Behaviour and Purchasing Patterns on Food, Non-Food, Drinks and Personal Care – ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Retail in China: Coronavirus (COVID-19) Country impact" report has been added to ResearchAndMarkets.com's…
6 years ago
Takeda to Present Data from the ICLUSIG® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML
– Oral Presentations of the Phase 2 OPTIC Interim Analysis at the American Society of…
6 years ago
Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS
– Pevonedistat Combination Demonstrates the Potential to Double Complete Remissions and Improve Outcomes in HR-MDS,…
6 years ago